BioLife Solutions (NASDAQ:BLFS) Upgraded at BidaskClub

BioLife Solutions (NASDAQ:BLFS) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday, November 7th, BidAskClub reports.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Other analysts also recently issued reports about the stock. Maxim Group set a $26.00 price objective on shares of BioLife Solutions and gave the company a “buy” rating in a report on Tuesday, September 17th. ValuEngine upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Zacks Investment Research downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th. HC Wainwright initiated coverage on shares of BioLife Solutions in a report on Monday, July 22nd. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, Northland Securities lifted their price objective on shares of BioLife Solutions from $18.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. BioLife Solutions presently has an average rating of “Buy” and an average price target of $18.40.

Shares of NASDAQ:BLFS traded up $0.50 during trading on Thursday, hitting $15.25. 226,500 shares of the company’s stock were exchanged, compared to its average volume of 159,355. The company has a current ratio of 6.49, a quick ratio of 7.71 and a debt-to-equity ratio of 0.01. BioLife Solutions has a 1-year low of $9.15 and a 1-year high of $22.44. The firm has a 50-day moving average price of $16.42 and a two-hundred day moving average price of $17.73. The firm has a market cap of $301.67 million, a P/E ratio of 108.93 and a beta of 1.35.

In related news, VP Todd Berard sold 3,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $20.02, for a total transaction of $60,060.00. Following the transaction, the vice president now directly owns 44,074 shares in the company, valued at $882,361.48. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Johan Wedell-Wedellsborg sold 17,243 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $27.00, for a total transaction of $465,561.00. Insiders sold 195,794 shares of company stock worth $3,629,637 over the last quarter. 27.00% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BLFS. FMR LLC acquired a new position in BioLife Solutions during the first quarter worth $2,684,000. WINTON GROUP Ltd increased its holdings in BioLife Solutions by 26.3% during the second quarter. WINTON GROUP Ltd now owns 22,118 shares of the medical equipment provider’s stock worth $375,000 after buying an additional 4,607 shares during the last quarter. Penbrook Management LLC acquired a new position in BioLife Solutions during the second quarter worth $493,000. Roubaix Capital LLC increased its holdings in BioLife Solutions by 165.9% during the second quarter. Roubaix Capital LLC now owns 120,313 shares of the medical equipment provider’s stock worth $2,039,000 after buying an additional 75,068 shares during the last quarter. Finally, Alpine Woods Capital Investors LLC acquired a new position in BioLife Solutions during the second quarter worth $170,000. Institutional investors and hedge funds own 45.62% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: What causes a stock to be most active?

Leave a Reply

Your email address will not be published. Required fields are marked *

*